Delaying initiation of adjuvant chemotherapy 91 or more days for patients with breast cancer can lead to adverse outcomes, especially among patients with triple-negative breast cancer. This according to a study of 24,843 patients with stage I to III invasive breast cancer and a median age at diagnosis of 53 years. Researchers found:
• Patients treated 91 or more days from surgery experienced worse overall survival (HR, 1.34) and worse breast cancer-specific survival (HR, 1.27).
• There was no evidence of adverse outcomes among patients with time to chemotherapy (TTC) of 31 to 60 days or 60 to 90 days.
• Longer TTC caused patients with triple-negative breast cancer to have worse overall survival (HR, 1.53) and worse breast cancer-specific survival (HR, 1.53).
Citation: Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. [Published online ahead of print December 10, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.3856.
This Week's Must Reads
Must Reads in Breast Cancer
Gender Images & Social Expectations in BC Diagnosis, Cancer; ePub 2018 Sep 24; Kim, Glassgow, et al
Predicting Mammography Adherence by Income Level, Women’s Health Issues; ePub 2018 Aug 8; Gathirua-Mwangi, et al
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al